Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | RRM1 | P23921 | 1/20 | 0.30 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20970306 | 0.80 | — | — | |
| SCHEMBL21733971 | 0.67 | NOS1 (0.30) | — | |
| SCHEMBL22328040 | 0.67 | — | — | |
| SCHEMBL17030765 | 0.64 | ADORA2A (0.35) | — | |
| SCHEMBL20132850 | 0.63 | CHEK1 (0.41) | — | |
| SCHEMBL22924129 | 0.62 | — | — | |
| SCHEMBL2492055 | 0.61 | TRPA1 (0.44) | — | |
| SCHEMBL17030769 | 0.59 | ADORA2A (0.37) | — | |
| SCHEMBL24024051 | 0.59 | CES2 (0.37) | — | |
| SCHEMBL3944819 | 0.59 | AR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | ARAXES PHARMA LLC (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | ARAXES PHARMA, LLC | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127336-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE | NRAS, KRAS, HRAS | CHRM2 4473/4885CHRM1 4696/4885RRM1 1382/4885 |
| US-10822312-B2 | Substituted quinazoline compounds and methods of use | NRAS, KRAS, HRAS | CHRM2 4370/4885CHRM1 4541/4885RRM1 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.